Environment, Inflammation and Metabolic Diseases Study

April 1, 2026 updated by: Qifu Li
The aim is to establish an effective and practical early warning model for endocrine and metabolic diseases based on an environmental-gene-protein panoramic network, to uncover new mechanisms underlying the onset and progression of these diseases, and to screen for novel therapeutic targets.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study aims to establish a specialized resource database for metabolic diseases-the Chongqing Environment, Inflammation, and Metabolic Diseases Study (EIMDS). The cohort will include approximately 8,000 community-based individuals who have been followed up for over 5 years, with clinical, biochemical, and endpoint event assessments conducted every two years, along with the collection of blood and urine samples. Based on the EIMDS cohort,this study will explore the risk factors for endocrine and metabolic diseases from a population perspective. Furthermore, by employing technologies such as whole-transcriptome sequencing, proteomics and phosphoproteomics, ATAC-seq, and single-cell sequencing,this study aim to elucidate the molecular mechanisms underlying endocrine and metabolic diseases and identify potential drug targets.

Study Type

Observational

Enrollment (Estimated)

8000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Qifu Li, MD, PhD, Chief Physician
  • Phone Number: 023-89011554 +8618696676815
  • Email: liqifu@yeah.net

Study Contact Backup

  • Name: Shumin Yang, MD, PhD, Chief Physician
  • Phone Number: 023-89011554 ‭+8615523552235‬
  • Email: 443068494@qq.com

Study Locations

  • China
      • Chongqing, China
        • Recruiting
        • The First Affiliated Hospital of Chongqing Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

This study aims to establish a specialized resource database-the Chongqing Environment, Inflammation, and Metabolic Diseases Study (EIMDS). The cohort will include approximately 8,000 community-based individuals who have been followed up for over 10 years. Clinical, biochemical, and endpoint event assessments will be conducted every two years, along with the collection of blood and urine specimens

Description

Inclusion Criteria:

  • All individuals who voluntarily participated in the physical examination

Exclusion Criteria:

Participants with incomplete data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
hypertension group
Participants with hypertension
Other: observe
A single observational cohort of study participants undergoing baseline biochemical screening for autonomous aldosterone secretion (AAS). No experimental interventions or treatments are administered. All participants receive standard clinical care and undergo standardized baseline assessments, including measurement of plasma aldosterone concentration (PAC) and plasma renin concentration (PRC) for AAS classification, as well as collection of demographic, clinical, biochemical, anthropometric data and biospecimens for proteomic analysis.
DM group
Participants with diabetes mellitus
Other: observe
A single observational cohort of study participants undergoing baseline biochemical screening for autonomous aldosterone secretion (AAS). No experimental interventions or treatments are administered. All participants receive standard clinical care and undergo standardized baseline assessments, including measurement of plasma aldosterone concentration (PAC) and plasma renin concentration (PRC) for AAS classification, as well as collection of demographic, clinical, biochemical, anthropometric data and biospecimens for proteomic analysis.
AAS group
Participants with autonomous aldosterone secretion (AAS)
Other: observe
A single observational cohort of study participants undergoing baseline biochemical screening for autonomous aldosterone secretion (AAS). No experimental interventions or treatments are administered. All participants receive standard clinical care and undergo standardized baseline assessments, including measurement of plasma aldosterone concentration (PAC) and plasma renin concentration (PRC) for AAS classification, as well as collection of demographic, clinical, biochemical, anthropometric data and biospecimens for proteomic analysis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The prevalence of autonomous secretion of aldosterone
Time Frame: The follow-up period from baseline enrollment to the completion of follow-up examinations was approximately 5 years
The primary outcome is the prevalence of autonomous aldosterone secretion at baseline. Autonomous aldosterone secretion is defined by plasma aldosterone concentration (PAC) ≥100 pg/mL combined with plasma renin concentration (PRC) ≤15 uIU/mL in study participants at enrollment. Prevalence will be calculated as the number of participants meeting the above biochemical criteria divided by the total enrolled participants in the target population, presented as percentage with corresponding 95% confidence interval.
The follow-up period from baseline enrollment to the completion of follow-up examinations was approximately 5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Identification of key risk factors associated with autonomous aldosterone secretion
Time Frame: The follow-up period from baseline enrollment to the completion of follow-up examinations was approximately 5 years
To identify independent demographic, clinical, biochemical, and anthropometric risk factors associated with prevalent autonomous aldosterone secretion.Autonomous aldosterone secretion is biochemically defined as plasma aldosterone concentration ≥100 pg/mL and plasma renin concentration ≤15 uIU/mL. Multivariable regression analysis will be applied to evaluate significant associated factors; effect sizes (e.g., odds ratio) with 95% confidence intervals and P-values will be reported.
The follow-up period from baseline enrollment to the completion of follow-up examinations was approximately 5 years
Association of autonomous aldosterone secretion with chronic kidney disease and metabolic disorders
Time Frame: The follow-up period from baseline enrollment to the completion of follow-up examinations was approximately 5 years
To evaluate the cross-sectional association between biochemically defined autonomous aldosterone secretion and chronic kidney disease as well as metabolic abnormalities in study participants at baseline. AAS is defined as plasma aldosterone concentration ≥100 pg/mL combined with plasma renin concentration ≤15 uIU/mL. Chronic kidney disease and metabolic disorders will be defined according to current clinical guidelines; relevant correlation and regression analyses will be performed to report effect sizes with 95% confidence intervals and P-values.
The follow-up period from baseline enrollment to the completion of follow-up examinations was approximately 5 years
Screening of key proteins, signaling pathways and potential biomarkers associated with autonomous aldosterone secretion using proteomic analysis
Time Frame: The follow-up period from baseline enrollment to the completion of follow-up examinations was approximately 5 years
To explore differentially expressed key proteins, enriched signaling pathways and candidate molecular biomarkers correlated with biochemical autonomous aldosterone secretion (AAS) via quantitative proteomic technology. AAS is defined as plasma aldosterone concentration ≥100 pg/mL and plasma renin concentration ≤15 uIU/mL. Bioinformatics analyses including protein differential expression profiling, functional enrichment analysis and pathway annotation will be performed to identify core molecular targets and potential diagnostic biomarkers for AAS.
The follow-up period from baseline enrollment to the completion of follow-up examinations was approximately 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Qifu Li

Investigators

  • Principal Investigator: Qifu Li, MD, PhD, Chief Physician, First Affiliated Hospital of Chongqing Medical University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 25, 2020

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

November 20, 2025

First Submitted That Met QC Criteria

April 1, 2026

First Posted (Actual)

April 6, 2026

Study Record Updates

Last Update Posted (Actual)

April 6, 2026

Last Update Submitted That Met QC Criteria

April 1, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EIMDS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on observe

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe